Log In
BCIQ
Print this Print this
 

IMGN632

  Manage Alerts
Collapse Summary General Information
Company ImmunoGen Inc.
DescriptionAntibody-drug conjugate targeting interleukin-3 (IL-3) receptor alpha (CD123)
Molecular Target Interleukin-3 (IL-3) receptor alpha (CD123)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myeloid leukemia (AML)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today